These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

916 related articles for article (PubMed ID: 15319021)

  • 1. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.
    Aman MG; Binder C; Turgay A
    J Child Adolesc Psychopharmacol; 2004; 14(2):243-54. PubMed ID: 15319021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of risperidone on conduct and disruptive behavior disorders in children with subaverage IQs.
    Snyder R; Turgay A; Aman M; Binder C; Fisman S; Carroll A;
    J Am Acad Child Adolesc Psychiatry; 2002 Sep; 41(9):1026-36. PubMed ID: 12218423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
    Loy JH; Merry SN; Hetrick SE; Stasiak K
    Cochrane Database Syst Rev; 2012 Sep; (9):CD008559. PubMed ID: 22972123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs.
    Turgay A; Binder C; Snyder R; Fisman S
    Pediatrics; 2002 Sep; 110(3):e34. PubMed ID: 12205284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence.
    Aman MG; De Smedt G; Derivan A; Lyons B; Findling RL;
    Am J Psychiatry; 2002 Aug; 159(8):1337-46. PubMed ID: 12153826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ.
    Findling RL; Aman MG; Eerdekens M; Derivan A; Lyons B;
    Am J Psychiatry; 2004 Apr; 161(4):677-84. PubMed ID: 15056514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy of disruptive behavior and item changes on a standardized rating scale: pooled analysis of risperidone effects in children with subaverage IQ.
    Aman M; Buitelaar J; Smedt GD; Wapenaar R; Binder C
    J Child Adolesc Psychopharmacol; 2005 Apr; 15(2):220-32. PubMed ID: 15910206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
    Loy JH; Merry SN; Hetrick SE; Stasiak K
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008559. PubMed ID: 28791693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response.
    Arnold LE; Gadow KD; Farmer CA; Findling RL; Bukstein O; Molina BS; Brown NV; Li X; Rundberg-Rivera EV; Bangalore S; Buchan-Page K; Hurt EA; Rice R; McNamara NK; Aman MG
    J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):203-12. PubMed ID: 25885010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study.
    Spencer TJ; Abikoff HB; Connor DF; Biederman J; Pliszka SR; Boellner S; Read SC; Pratt R
    Clin Ther; 2006 Mar; 28(3):402-18. PubMed ID: 16750455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression.
    Masi G; Manfredi A; Nieri G; Muratori P; Pfanner C; Milone A
    J Clin Psychopharmacol; 2017 Oct; 37(5):590-594. PubMed ID: 28806385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Children with ADHD and symptoms of oppositional defiant disorder improved in behavior when treated with methylphenidate and adjuvant risperidone, though weight gain was also observed - Results from a randomized, double-blind, placebo-controlled clinical trial.
    Jahangard L; Akbarian S; Haghighi M; Ahmadpanah M; Keshavarzi A; Bajoghli H; Sadeghi Bahmani D; Holsboer-Trachsler E; Brand S
    Psychiatry Res; 2017 May; 251():182-191. PubMed ID: 28213188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attendance and Engagement in Parent Training Predict Child Behavioral Outcomes in Children Pharmacologically Treated for Attention-Deficit/Hyperactivity Disorder and Severe Aggression.
    Joseph HM; Farmer C; Kipp H; Kolko D; Aman M; McGinley J; Arnold LE; Gadow KD; Findling RL; Molina BSG
    J Child Adolesc Psychopharmacol; 2019 Mar; 29(2):90-99. PubMed ID: 30592635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder.
    Farmer CA; Brown NV; Gadow KD; Arnold LE; Kolko DG; Findling RL; Molina BS; Buchan-Page KA; Rice RR; Bangalore SS; Bukstein O; Rundberg-Rivera EV; McNamara N; Aman MG
    J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):213-24. PubMed ID: 25885011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risperidone in children with disruptive behavior disorders and subaverage intelligence: a 1-year, open-label study of 504 patients.
    Croonenberghs J; Fegert JM; Findling RL; De Smedt G; Van Dongen S;
    J Am Acad Child Adolesc Psychiatry; 2005 Jan; 44(1):64-72. PubMed ID: 15608545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risperidone-to-methylphenidate switch reaction in children: three cases.
    Sabuncuoglu O
    J Psychopharmacol; 2007 Mar; 21(2):216-9. PubMed ID: 17329303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents.
    Haas M; Karcher K; Pandina GJ
    J Child Adolesc Psychopharmacol; 2008 Aug; 18(4):337-45. PubMed ID: 18759643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders.
    Reyes M; Buitelaar J; Toren P; Augustyns I; Eerdekens M
    Am J Psychiatry; 2006 Mar; 163(3):402-10. PubMed ID: 16513860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety, and tolerability.
    Reyes M; Croonenberghs J; Augustyns I; Eerdekens M
    J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):260-72. PubMed ID: 16768634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risperidone and cognitive function in children with disruptive behavior disorders.
    Pandina GJ; Bilder R; Harvey PD; Keefe RS; Aman MG; Gharabawi G
    Biol Psychiatry; 2007 Aug; 62(3):226-34. PubMed ID: 17210137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.